FDA May End Expert Panel Reviews for New Drug Approvals

The Food and Drug Administration under President Trump's administration is considering eliminating the decades-old practice of convening outside expert panels to review new drug applications. George Tidmarsh, head of the FDA's Center for Drug Evaluation and Research, stated at recent industry meetings that these advisory committees for individual drugs are redundant and resource-intensive. The FDA has instead begun publishing previously private rejection letters to pharmaceutical companies as an alternative transparency measure.